Gregory Conn
Chief Tech/Sci/R&D Officer at PDS BIOTECHNOLOGY CORPORATION
Net worth: 457 558 $ as of 31/03/2024
Profile
Gregory L.
Conn is the founder of PDS Operating Corp.
He is currently the Chief Scientific Officer at PDS Biotechnology Corp.
He previously worked as the Director of the Process Development Department at Covance Biotechnology Services, Inc. from 1998 to 2000.
Dr. Conn holds a graduate and doctorate degree from Albert Einstein College of Medicine, Inc.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PDS BIOTECHNOLOGY CORP.
0.37% | 05/01/2023 | 115,545 ( 0.37% ) | 457 558 $ | 31/03/2024 |
Gregory Conn active positions
| Companies | Position | Start |
|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Chief Tech/Sci/R&D Officer | 15/03/2019 |
Former positions of Gregory Conn
| Companies | Position | End |
|---|---|---|
Covance Biotechnology Services, Inc.
 Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ. | Corporate Officer/Principal | 01/01/2000 |
PDS Operating Corp.
 PDS Operating Corp. BiotechnologyHealth Technology PDS Operating Corp. operates as a biopharmaceutical company. It develops immunotherapies for cancer and infectious disease. The firm’s versamune is capable of potent activation of immune cells without the side effects of traditional vaccines, efficiently delivering disease related antigen targets to the immune system and promoting antigen processing to present antigen appropriately to generate both strong prophylactic and therapeutic immune responses to disease. The company was founded by Frank K. Bedu-Addo and Gregory L. Conn and is headquartered in Princeton, NJ. | Founder | - |
Training of Gregory Conn
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Health Technology |
| Private companies | 2 |
|---|---|
PDS Operating Corp.
PDS Operating Corp. BiotechnologyHealth Technology PDS Operating Corp. operates as a biopharmaceutical company. It develops immunotherapies for cancer and infectious disease. The firm’s versamune is capable of potent activation of immune cells without the side effects of traditional vaccines, efficiently delivering disease related antigen targets to the immune system and promoting antigen processing to present antigen appropriately to generate both strong prophylactic and therapeutic immune responses to disease. The company was founded by Frank K. Bedu-Addo and Gregory L. Conn and is headquartered in Princeton, NJ. | Health Technology |
Covance Biotechnology Services, Inc.
Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ. | Health Technology |
- Stock Market
- Insiders
- Gregory Conn
